Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

NCT05353439 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

NIH

Sponsor class

Conditions

Extensive Stage Lung Small Cell Carcinoma
Limited Stage Lung Small Cell Carcinoma
Platinum-Resistant Lung Small Cell Carcinoma
Platinum-Sensitive Lung Small Cell Carcinoma
Recurrent Extensive Stage Lung Small Cell Carcinoma
Recurrent Lung Small Cell Carcinoma

Interventions

PROCEDURE: Biopsy Procedure
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
BIOLOGICAL: Pembrolizumab
DRUG: Tazemetostat Hydrobromide
DRUG: Topotecan Hydrochloride

Sponsor

National Cancer Institute (NCI)